Found 55 articles
11/13/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Elicio Therapeutics Announces Poster Presentation at 2020 Society for Immunotherapy of Cancer Annual Meeting
Elicio Therapeutics , a next generation immunotherapy company, today announced virtual poster presentations for the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting November 9-14, 2020. The presentations will update progress in two IND-ready programs demonstrating the broad application of Elicio’s Amphiphile Platform, one for a protein subunit vaccine for COVID-19; the other targeting the seven mutations c
Elicio Therapeutics, a next generation immuno-oncology company, announced that it has established a collaboration with the Moffitt Cancer Center to characterize combination therapies pairing Elicio’s CD19 Amphiphile and a universal FITC Amphiphile with CD19 CAR T cells.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 19, 2020.
Lymph Node Targeting COVID-19 Vaccine Induces Up To 25-Fold More T Cells Over Benchmark Vaccines and >265-Fold Greater Antibody Levels Than Recovering Patients
Preclinical data from a lymph node targeted COVID-19 vaccine candidate showed potent CD8 and CD4 T Cells in lung tissue and respiratory fluid
Elicio Therapeutics and National Cancer Institute Collaborate to Study ELI-002 Mutant KRAS Targeting Mechanism
Elicio Therapeutics, a next generation immuno-oncology company, announced that it has established a collaboration with the National Cancer Institute to characterize T cell responses to ELI-002 in animals.
Elicio Therapeutics to Discuss Novel Lymph Node Vaccine Targeting Seven Key mKRAS Mutations at RAS - Targeted Drug Discovery Summit in Vienna, Austria
Elicio Therapeutics, a next generation immuno-oncology company, today announced Peter DeMuth, PhD., Elicio Vice President of Research, will present “Targeting the Lymph Nodes to Enhance Mutant KRAS-Specific Vaccine Responses,” at the upcoming RAS-Targeted Drug Discovery Summit in Vienna, Austria, from February 25 to 27, 2020.
2/17/2020It was a very busy week for clinical trial news. Here’s a look.
Signatera test used for patient selection and monitoring to accelerate molecular proof of concept [11-February-2020] CAMBRIDGE , Mass. and SAN CARLOS, Calif. , Feb. 11, 2020 /PRNewswire/ -- Elicio Therapeutics , a next generation immuno-oncology company, and Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced their collabora
Physician-Scientist Christopher Haqq M.D., Ph.D. Joins Elicio Therapeutics as Research and Development Head
Elicio Therapeutics, a next generation immuno-oncology company, announced today that Christopher Haqq M.D., Ph.D. has joined Elicio as Executive Vice President, Head of Research and Development, and Chief Medical Officer.
Elicio Therapeutics, a next generation immuno-oncology company, announced today that it has closed its $33 million Series B financing. Proceeds from the financing will be used to advance Elicio’s pipeline of novel lymph node targeted immuno-therapies, including ELI-002, an Amphiphile mKRAS vaccine (AMP KRAS). ELI-002 targets all seven KRAS mutations that drive 99% of all mKRAS-driven cancers, estimated to be 25% of all human solid tumors.
Elicio Therapeutics Presents In Vivo Data for a Universal Amphiphile Vaccine Targeting KRAS-Driven Cancers
Phase One patient data from a potential therapy targeting a single KRAS mutation, formerly considered “undruggable,” has been introduced in 2019.
Elicio Therapeutics Co-founder, Darrell Irvine, Co-authors Research Published in Science Demonstrating Novel AMP-CAR-T Approach to Enhance CAR-T Function in Solid Tumor Cancers
Elicio Therapeutics, today announced that studies of its Amphiphile platform in combination with CAR-T therapy (AMP-CAR-T) have shown that activation of CAR-T cells in the lymphatic system gives massive CAR-T cell expansion, and significant functional improvements including enhanced CAR-T cell infiltration of solid tumors, increased anti-tumor cytolytic potential, and improved cytokine response.
Windtree Therapeutics, Inc., announced it has appointed Daniel Geffken to the Company's Board of Directors, effective April 24, 2019.
Immuno-Oncology Company Elicio Therapeutics Launches with Novel Vaccine & Immunotherapy Platform to Treat an Array of Cancers
Elicio Therapeutics, a next generation immuno-oncology company, engineering therapies for cancer killing immune responses, launched today and announced the appointment of Robert Connelly as CEO.